SRx Health Solutions Redeems Series A Preferred Stock and Cancels Approximately 125,000,000 Shares of Common Stock, Improving Balance Sheet Flexibility for Investment in M&A or Return of Capital to Shareholders
SRx Health Solutions (NYSE:SRXH) redeemed 17,500 shares of its Series A preferred stock on Feb 11, 2026, which represented approximately 125,000,000 common shares on an as-converted basis and were cancelled.
Rhea-AI Summary
SRx Health Solutions (NYSE:SRXH) redeemed 17,500 shares of its Series A preferred stock on Feb 11, 2026, which represented approximately 125,000,000 common shares on an as-converted basis and were cancelled. The Series A had been sold in a private placement on Oct 31, 2025 for about $15.23 million. The company said the retirement and cancellation improve capital structure flexibility to support future investments or potential returns to shareholders. SRXH also expects to file its Form 10-Q for the quarter ended Dec 31, 2025 on Feb 13, 2026.
Positive
- Redeemed 17,500 Series A preferred shares, removing ~125,000,000 potential common shares
- Improves capital structure flexibility for future investments or shareholder returns
- Private placement raised approximately $15.23 million used in connection with the Series A issuance
Negative
- No immediate undisclosed M&A plans as of Feb 11, 2026, limiting near-term transaction visibility
Details
News Market Reaction – SRXH
On Feb 11, the day this news came out, SRXH closed 16.24% below the previous close.
Data tracked by StockTitan Argus for the Feb 11 session.
Key Figures
- Series A preferred redeemed
- 17,500 shares
- Redeemed pursuant to Series A terms, tied to common on as-converted basis
- Common shares cancelled
- 125,000,000 shares
- Approximate common shares on an as-converted basis cancelled via redemption
- Preferred issued
- 19,035 shares
- Series A Preferred sold in private placement on Oct 31, 2025
- Private placement proceeds
- $15.23 million
- Aggregate proceeds from Oct 31, 2025 Series A Preferred private placement
- Crypto portfolio size
- $18 million
- Previously disclosed Bitcoin and Ethereum holdings in treasury strategy
- Resale registration (Keystone)
- 2,506,893,959 shares
- Common stock registered for resale by Keystone Capital Partners
- Equity line capacity
- $1.0 billion
- Potential common share sales under equity line of credit structure
- Annual net sales
- $6.5 million
- Net sales from continuing operations year ended Sep 30, 2025
Historical Context
-
Launch of EventHorizonIQ ledger for AI-generated financial instability signals.
-
Significant reduction of short positions in Bitcoin and Ethereum portfolio.
-
Additional capital allocated to digital assets, bringing holdings to $18M.
-
Investment in Opendoor common stock as part of capital allocation strategy.
-
Announcement of virtual fireside chat on EMJX treasury OS strategy.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
series a preferred stock financial
private placement financial
form 10-q regulatory
pipe financings financial
equity line of credit financial
convertible note financial
going concern financial
ccaa restructuring regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
NORTH PALM BEACH, Fla., Feb. 11, 2026 (GLOBE NEWSWIRE) -- SRx Health Solutions, Inc. (NYSE American: SRXH) (the "Company") today announced that it has redeemed 17,500 shares of its Series A Preferred Stock pursuant to the terms of the Series A Preferred Stock, representing approximately 125,000,000 shares of common stock on an as-converted basis. On October 31, 2025 the Company issued and sold in a private placement 19,035 shares of the Series A Preferred Stock for aggregate proceeds of approximately
The Company expects to file its Form 10-Q with the SEC for its fiscal first quarter for the period ended December 31, 2025 on Friday, February 13, 2026.
Michael Young, Board Member of SRx Health, commented, “The retirement of the preferred and cancellation of approximately 125,000,000 shares of common stock allows for further flexibility of our capital structure for additional investments in the future.”
SRXH does not have immediate plans for M&A as of the date of this release that has not been already disclosed, but will continue to evaluate opportunities from time to time.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “believe,” “expect,” “intend,” “aim,” “plan,” “may,” “could,” “target,” and similar expressions are intended to identify forward-looking statements. These statements are based on current expectations and assumptions that are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied. These risks include, but are not limited to, the ability to complete the proposed transaction, shareholder approvals, market conditions, regulatory considerations, and other risks described in the Company’s filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date made, and the Company undertakes no obligation to update them, except as required by law.
Company Contact
SRx Health Solutions, Inc.
Kent Cunningham, Chief Executive Officer
Investor Relations Contact
KCSA Strategic Communications
Valter Pinto, Managing Director
212-896-1254
valter@kcsa.com
Media Contact
KCSA Strategic Communications
Kristin Cwalinski, Senior Vice President
EMJX@KCSA.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.